<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01133158</url>
  </required_header>
  <id_info>
    <org_study_id>R-BMD GELTAMO 08</org_study_id>
    <nct_id>NCT01133158</nct_id>
  </id_info>
  <brief_title>R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial</brief_title>
  <official_title>Study Phase II Non-randomized Prospective Open to Assess the Combination of Rituximab, Bendamustine, Mitoxantrone, Dexamethasone (R-BMD) in Patients With Follicular Lymphoma Refractory or Relapsed</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the combination of efficacy of the combination of rituximab, bendamustine,
      mitoxantrone, dexamethasone in the treatment of patients with Follicular Lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assess the combination of efficacy and safety of the combination of rituximab, bendamustine,
      mitoxantrone, dexamethasone in the treatment of patients with Follicular Lymphoma who are
      refractory or in relapse.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>7 years</time_frame>
    <description>The primary endpoint is the number of Participants with Response according to the criteria of the International Workshop to Standardize Response Criteria for NHL
Complete Remission (CR):
Nodes returned to normal (if GTD &gt;15 mm before therapy, GTD now ≤15 mm; if GTD 11-15 and SA &gt;10 mm before therapy, SA now ≤10 mm) All (non-nodal) target lesions completely resolved
Partial Remission (PR) SPD of target lesions decreased ≥50% from baseline Spleen and liver nodules regress by 50% in SPD or single lesion in GTD
Stable Disease (SD) Not enough shrinkage for PR Not enough growth for PD
Progressive Disease (PD):
SPD increase ≥50% from nadir (smallest value seen during trial) in nodal target lesions overall or in any single nodal target lesion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoints Included an Assessment of the Following Parameters: Progression-Free Survival, Disease-Free Survival, Global Survival, Duration of the Response.</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>R-BMD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab, Bendamustine, Mitoxantrone, Dexamethasone Induction: 6 Rituximab, Bendamustine, Mitoxantrone, Dexamethasone cycles Maintenance: Rituximab every 3 months for 2 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab, Bendamustine, Mitoxantrone, Dexamethasone</intervention_name>
    <description>Bendamustine: 90 mg/m2/day, days 1 and 2 of each cycle, iv Mitoxantrone: 6 mg/m2/day, day 1 of each cycle, iv Dexamethasone 20 mg / day, days 1 through 5 of each cycle, od Rituximab: 375 mg / m 2 / day, day 1 of each cycle, iv</description>
    <arm_group_label>R-BMD</arm_group_label>
    <other_name>R-BMD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 and ≤ 75 years.

          2. Patients with follicular lymphoma grade 1, 2 or 3a, CD20 +, histologically confirmed
             lymph node biopsy or tissue. Be accepted diagnosis in bone marrow if no accessible
             lymph nodes and whether it has discarded the mantle LLC, and NHL.

          3. Follicular lymphoma patients treated with the combination of rituximab and
             chemotherapy in first line, which have been refractory or relapsed after having
             achieved any responses to this first line of pretreatment (excluding radiotherapy).

          4. ECOG ≤ 2.

          5. Signed written informed consent.

        Exclusion Criteria:

          1. Clinical suspicion or documentation of histological transformation.

          2. Have received prior chemotherapy scheme, first line without Rituximab.

          3. Prior autologous or allogeneic.

          4. CNS infiltration by LF (primary CNS lymphoma or lymphomatous meningitis).

          5. Past or active Hepatitis B (at least one of the following markers HBsAg, HBe Ag,
             anti-HBc, HBV DNA)

          6. HCV infection. HIV infection or other conditions of serious immunosuppression.

          7. Previous neoplasms except non-melanoma skin cancer of the cervix or adequately
             treated.

          8. Cardiac function in cardiac patient known or prior treatment with anthracyclines with
             EF &lt;50%.

          9. Impaired renal function (creatinine&gt; 1.5 x Upper Limit of Normal, LSN) or a creatinine
             clearance &lt;50 ml / h, not related to lymphoma.

         10. Impaired liver function (bilirubin, AST / ALT or GGT&gt; 2 x ULN) were not related to
             lymphoma.

         11. Women who are nursing or pregnant. Women of childbearing potential will be included
             prior pregnancy test serum / urine negative. Use effective contraception to be kept
             for 1 year after cessation of rituximab.

         12. Patients with heart disease, pulmonary, neurological, psychiatric or severe metabolic
             and not secondary to lymphoma.

         13. Severe acute or chronic infection in activity.

         14. Any other concurrent medical or psychological comorbidity that might interfere with
             participation in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Javier Peñalver Párraga, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Fundación Alcorcón</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier De la Serna Torroba, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital 12 de Octubre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisca Oña Compan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Getafe.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patricia Font López, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gregorio Marañón Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Secundino Ferrer Bordas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Dr. Peset</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Ramón Mayans Ferrer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Arnau de Vilanova</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eulogio Conde García, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Marqués de Valdecilla</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Antonio Márquez Navarro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Basurto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ernesto Pérez Persona, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Txagorritxu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Garazi Letamendi Madariaga, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Galdakao</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pilar Giraldo Castellanos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Miguel Servet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis Palomera Bernal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico de Zaragoza</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrés López Hernández, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d´Hebron</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Blanca Sánchez González, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital del Mar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Luis Sánchez-Majado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital San Juan de Alicante</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Gutiérrez García, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Son Espases</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco Javier Capote Huelva, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Puerta del Mar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fátima de la Cruz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Virgen del Rocío</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mª José Ramírez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Jerez</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando Carnicero González, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital San Pedro de Alcántara</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mª José Rodríguez Salazar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Canarias</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miguel Ángel Canales Albendea, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital La Paz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Antonio García Marco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Puerta de Hierro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Montalbán Sanz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Ramon y Cajal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rosalía Riaza Grau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Severo Ochoa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mª Dolores Caballero Barrigón, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Salamanca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mª Jesús Peñarrubia Ponce, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Río Hortega</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Antonio Queizán, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Segovia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Hernández Martín, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Virgen de la Concha</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mª José Terol Castera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Félix Carbonell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>María Rosario Varela Gómez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Hospitalario A Coruña</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Luis Bello López, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>C. H. U. Santiago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Panizo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clínica Universitaria de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Manuel Sancho Cia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Germans Trias i Pujol Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Armando López Guillermo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínic i Provincial</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elena Pérez Ceballos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Morales Meseguer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrés Sánchez Salinas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen de la Arrixaca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mª Soledad Durán Nieto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Jaén</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuel Espeso de Haro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Carlos Haya</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joan Bargay Lleonart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Son Llàtzer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Txagorritxu</name>
      <address>
        <city>Vitoria</city>
        <state>Alava</state>
        <zip>01009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Juan de Alicante</name>
      <address>
        <city>San Juan de Alicante</city>
        <state>Alicante</state>
        <zip>03550</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Galdakao</name>
      <address>
        <city>Galdakao</city>
        <state>Bilbao</state>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Jerez</name>
      <address>
        <city>Jerez de la Frontera</city>
        <state>Cádiz</state>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Fundación de Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <state>Madrid</state>
        <zip>289222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Getafe</name>
      <address>
        <city>Getafe</city>
        <state>Madrid</state>
        <zip>28901</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Severo Ochoa</name>
      <address>
        <city>Leganés</city>
        <state>Madrid</state>
        <zip>28911</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llàtzer</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Mallorca</state>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Mallorca</state>
        <zip>07014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d´Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Basurto</name>
      <address>
        <city>Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro Alcántara</name>
      <address>
        <city>Cáceres</city>
        <zip>10002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta del Mar</name>
      <address>
        <city>Cádiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Carlos Haya</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Segovia</name>
      <address>
        <city>Segovia</city>
        <zip>42002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Peset</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Río Hortega</name>
      <address>
        <city>Valladolid</city>
        <zip>47012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Concha</name>
      <address>
        <city>Zamora</city>
        <zip>49022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Zaragoza</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>February 11, 2010</study_first_submitted>
  <study_first_submitted_qc>May 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2010</study_first_posted>
  <results_first_submitted>March 7, 2017</results_first_submitted>
  <results_first_submitted_qc>February 21, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 1, 2018</results_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Follicular non-Hodgkin's lymphoma relapse refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rituximab, Bendamustine, Mitoxantrone, Dexamethasone</title>
          <description>Patient will receive Rituximab, Bendamustina, Mitoxantrone and Dexametasona
Rituximab, Bendamustine, Mitoxantrone, Dexamethasone: Bendamustine: 90 mg/m2/day, days 1 and 2 of each cycle, iv Mitoxantrone: 6 mg/m2/day, day 1 of each cycle, iv DEXAMETHASONE 20 mg / day, days 1 through 5 of each cycle, od Rituximab: 375 mg / m 2 / day, day 1 of each cycle, iv</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rituximab, Bendamustine, Mitoxantrone, Dexamethasone</title>
          <description>Patient will receive Rituximab, Bendamustina, Mitoxantrone and Dexametasona
Rituximab, Bendamustine, Mitoxantrone, Dexamethasone: Bendamustine: 90 mg/m2/day, days 1 and 2 of each cycle, iv Mitoxantrone: 6 mg/m2/day, day 1 of each cycle, iv DEXAMETHASONE 20 mg / day, days 1 through 5 of each cycle, od Rituximab: 375 mg / m 2 / day, day 1 of each cycle, iv</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="32" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate</title>
        <description>The primary endpoint is the number of Participants with Response according to the criteria of the International Workshop to Standardize Response Criteria for NHL
Complete Remission (CR):
Nodes returned to normal (if GTD &gt;15 mm before therapy, GTD now ≤15 mm; if GTD 11-15 and SA &gt;10 mm before therapy, SA now ≤10 mm) All (non-nodal) target lesions completely resolved
Partial Remission (PR) SPD of target lesions decreased ≥50% from baseline Spleen and liver nodules regress by 50% in SPD or single lesion in GTD
Stable Disease (SD) Not enough shrinkage for PR Not enough growth for PD
Progressive Disease (PD):
SPD increase ≥50% from nadir (smallest value seen during trial) in nodal target lesions overall or in any single nodal target lesion</description>
        <time_frame>7 years</time_frame>
        <population>Number of Participants analyzed in the Maintenance Rituximab Arm reflects all participants who received at least one dose of Rituximab during maintenance, and had available data for response during that phase</population>
        <group_list>
          <group group_id="O1">
            <title>Induction Rituximab, Bendamustine, Mitoxantrone, Dexamethasone</title>
            <description>Patient will receive Rituximab, Bendamustina, Mitoxantrone and Dexametasona
Rituximab, Bendamustine, Mitoxantrone, Dexamethasone: Bendamustine: 90 mg/m2/day, days 1 and 2 of each cycle, iv Mitoxantrone: 6 mg/m2/day, day 1 of each cycle, iv DEXAMETHASONE 20 mg / day, days 1 through 5 of each cycle, od Rituximab: 375 mg / m 2 / day, day 1 of each cycle, iv</description>
          </group>
          <group group_id="O2">
            <title>Maintenance Rituximab</title>
            <description>Patient who had response to induction will receive Rituximab in maintenance
Rituximab: 375 mg / m2 every three months</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>The primary endpoint is the number of Participants with Response according to the criteria of the International Workshop to Standardize Response Criteria for NHL
Complete Remission (CR):
Nodes returned to normal (if GTD &gt;15 mm before therapy, GTD now ≤15 mm; if GTD 11-15 and SA &gt;10 mm before therapy, SA now ≤10 mm) All (non-nodal) target lesions completely resolved
Partial Remission (PR) SPD of target lesions decreased ≥50% from baseline Spleen and liver nodules regress by 50% in SPD or single lesion in GTD
Stable Disease (SD) Not enough shrinkage for PR Not enough growth for PD
Progressive Disease (PD):
SPD increase ≥50% from nadir (smallest value seen during trial) in nodal target lesions overall or in any single nodal target lesion</description>
          <population>Number of Participants analyzed in the Maintenance Rituximab Arm reflects all participants who received at least one dose of Rituximab during maintenance, and had available data for response during that phase</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Endpoints Included an Assessment of the Following Parameters: Progression-Free Survival, Disease-Free Survival, Global Survival, Duration of the Response.</title>
        <time_frame>7 years</time_frame>
        <population>Only those patients who started the maintenance treatmet were analyzed for Disease-Free Survival</population>
        <group_list>
          <group group_id="O1">
            <title>R-BMD</title>
            <description>Rituximab, Bendamustine, Mitoxantrone, Dexamethasone Induction: 6 Rituximab, Bendamustine, Mitoxantrone, Dexamethasone cycles Maintenance: Rituximab every 3 months for 2 years
Rituximab, Bendamustine, Mitoxantrone, Dexamethasone: Bendamustine: 90 mg/m2/day, days 1 and 2 of each cycle, iv Mitoxantrone: 6 mg/m2/day, day 1 of each cycle, iv Dexamethasone 20 mg / day, days 1 through 5 of each cycle, od Rituximab: 375 mg / m 2 / day, day 1 of each cycle, iv</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Endpoints Included an Assessment of the Following Parameters: Progression-Free Survival, Disease-Free Survival, Global Survival, Duration of the Response.</title>
          <population>Only those patients who started the maintenance treatmet were analyzed for Disease-Free Survival</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Progression-Free Survival</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="28" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease-Free Survival</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="36" upper_limit="NA">Insufficient number of participants with events. Superior data to Disease-Free Survival is still not available</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global Survival</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Insufficient number of participants with events. Global Survival data is still not available</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of the Response</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="36" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rituximab, Bendamustine, Mitoxantrone, Dexamethasone</title>
          <description>Patient will receive Rituximab, Bendamustina, Mitoxantrone and Dexametasona
Rituximab, Bendamustine, Mitoxantrone, Dexamethasone: Bendamustine: 90 mg/m2/day, days 1 and 2 of each cycle, iv Mitoxantrone: 6 mg/m2/day, day 1 of each cycle, iv DEXAMETHASONE 20 mg / day, days 1 through 5 of each cycle, od Rituximab: 375 mg / m 2 / day, day 1 of each cycle, iv
Patients with response will receive Rituximab in maintenance: 375 mg / m2 every three months</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Oral ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="20" subjects_affected="12" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Progression suspicion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Immunodeficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Leucoencephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neuropathy caranial-CN VII</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal insufficiency</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="318" subjects_affected="50" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="144" subjects_affected="43" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>plateletes</sub_title>
                <counts group_id="E1" events="135" subjects_affected="41" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>other</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>hearing</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="21" subjects_affected="11" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="58" subjects_affected="21" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="36" subjects_affected="18" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="25" subjects_affected="20" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="79" subjects_affected="40" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic/laboratory</sub_title>
                <counts group_id="E1" events="82" subjects_affected="45" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>mood alteration</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>cold</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>dispnea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>mucositis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>pruritus/itching</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Francisco Javier Peñalver</name_or_title>
      <organization>GELTAMO</organization>
      <phone>91 621 98 24</phone>
      <email>fjpenalver@fhalcorcon.es</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

